Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...